Hello everyone, this is my first post here, although I do
Hello everyone, this is my first post here, although I do post elsewhere under the nom de guerre 'Bridge to Sell'. This is a recap of a thought that I recently shared with a friend and fellow CYDY investor. In the interest of full disclosure I have a significant long position in CYDY.
Basically my premise was that in the early days of the CD12 trial we had higher s/c mortality because standard of care had only just begun to be worked out. Naturally that would imply that as time went on mortality in this patient population would start to drop, making it harder to hit statistical relevance. This has been discussed here and elsewhere ad nauseum.
However, because of his success with Leronlimab we had Dr. Nicholas Agresti travelling the country to each of the 18 trial sites in the Fall. Remember, this is the same Dr. Agresti who had a paper accepted in the Journal of Translational Autoimmunity about Leronlimab. Dr. Agresti has been credited with single handedly filling up the second half of the trial and getting us to full enrollment.
So we had a doctor who has successfully used the drug travelling around the country explaining to other doctors how the drug works and on whom they should be targeting it in order to save lives. I believe that it is for that reason alone that we did not see fewer deaths in the second half of the trial because of SOC mitigation. At 195 patient enrollment there were 45 deaths, and at the end of trial there have been 88 deaths for 394 patients.
The ONLY explanation is that Dr. Agresti made sure that the inclusion criteria for the second half of the trial included patients that skewed to more critical than severe. Otherwise standard of care would have dictated that fewer severe patients progressed to critical and deaths as a percentage would have dropped somewhat.
Thanks for reading.
14
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Leidos Sets Sights on Boosting U.S. Missile Production There's big news out of Reston, Virginia, that should make investors sit up and take notice. Leidos (NYSE: LDOS) is revving up the supply chain engines to churn out thousands of long-range cruise missiles, specifically the new Low-Cost Containerized Missile (LCCM) and the combat-time-tested AGM-190A Havoc Spear...
Continue Reading
A Big Play in the Valve Game Straight out of the industrial playbook, Platinum Equity swoops in with its latest acquisition of Warren Valve, yanking it from the clutches of Allied Group. It's not every day you see a move like this in the flow control world. Yeah, you heard that right—flow control. The kind of business that’s all about ensuring the right stuff gets to...
Continue Reading
New Crosshairs on Coastal Financial Corporation Man, it's another day and yet another fiasco in the corporate world. Late-breaking news from the trenches alerts us that Coastal Financial Corporation is in the legal spotlight. Yeah, you heard me right. We're talking about NASDAQ:CCB, the darlings turned defendants courtesy of recent allegations that could rock their stock....
Continue Reading
Innovation Steals the Show in Guangzhou In a world where tech evolution rarely takes a breather, the 140th Canton Fair's Intelligent Healthcare Zone is like a breath of fresh air. Picture it: a whole arena pulsing with futuristic healthcare gizmos from October 31 to November 4, 2026—it's as if tomorrow swung by for a sneak peek. The event brings together everything from...
Continue Reading
A New Serving in Spanish Fork Chicken Salad Chick is taking another bite out of the Utah market with the opening of its second location in Spanish Fork. On deck for a November 17 debut, this fast-casual chain is serving up not just chicken salad, but a hefty dose of Southern hospitality and promotional giveaways to boot. The big hook? Be among the first 100 patrons and...
Continue Reading
Breaking Down the Results The SIRONA trial has thrown some revealing numbers our way about treating femoropopliteal artery disease. MagicTouch PTA, a sirolimus-coated balloon developed by Concept Medical, seems to be giving paclitaxel-coated balloons a run for their money, thanks to new data from Research Tokyo 2026. What the Numbers Show After three years, the data shows...
Continue Reading
Steering Parkview into New Waters Every now and then, a company gets a leader who feels like a tailor-made fit for its ambitions. Parkview Dental Partners just scored big with Jon Gregoire taking the helm as CEO. Gregoire, a seasoned DSO bigwig with a knack for M&A, is set to power up the gears for Parkview’s next growth spurt. We're talking about a guy who knows the...
Continue Reading
Taking a Gamble on AI's New Kid on the Block Here we stand on the edge of another potential AI stock bonanza. Anthropic’s got its sights set on going public, and folks are lining up to bite into what could be the next big generative AI feast. But it's Leverage Shares by Themes that's setting the scene for something a bit wilder—introducing some juicy leveraged and...
Continue Reading
MEDICA 2026: Wincomm and Portwell Join Forces November's got one heck of an event lined up with MEDICA 2026, where Wincomm and Portwell are teaming up to showcase what they've got up their sleeves in medical AI computing. This whole shebang runs from November 16 to 19, with their setup in Hall 12, Stand C76, Düsseldorf, Germany. But why should investors care? Because...
Continue Reading
Blazing Solar Trails in the Digital Landscape Lend an ear, folks, because Beyon's latest leap in the world of renewable energy isn't just another 'look how green we are' maneuver. Announced during Gateway Gulf 2026, this venture is all about serious numbers and even more serious energy chops. Beyon's on course to power a third data center entirely through solar energy,...
Continue Reading
Top 5 Most Recently Viewed Articles
Delta Dental of California Acknowledged for Workplace Excellence Delta Dental of California has recently been recognized as one of the top workplaces for women by Newsweek. This esteemed acknowledgment highlights the organization’s enduring dedication to fostering an inclusive environment, supporting employee wellbeing, and driving innovation in the healthcare sector. A...
Continue Reading
Recent Shareholding Changes at Umicore Umicore, a prominent player in materials technology, has recently received important notifications regarding changes in shareholding from two major financial institutions: BlackRock, Inc. and Bank of America Corp. These notifications play a crucial role in ensuring transparency and offer insights into how shifts in ownership can...
Continue Reading
Gran Tierra Energy Inc. Announces Strategic Share Buyback Plan Gran Tierra Energy Inc. (NYSE: GTE) has unveiled its strategy regarding a normal course issuer bid (the "Bid") aimed at buying back its common stock. The Toronto Stock Exchange (TSX) has given its approval for this initiative, allowing the company to purchase shares for cancellation or to satisfy long-term...
Continue Reading
Understanding Colgate-Palmolive's Quarterly Earnings Release Colgate-Palmolive (NYSE: CL) is preparing for its quarterly earnings announcement, which many investors are keenly anticipating. With expectations set for the company to report an earnings per share (EPS) of $0.88, this release could carry significant implications for the stock's short-term direction. Investors...
Continue Reading
Transforming Talent Acquisition Technology in 2024 The talent acquisition technology landscape is undergoing a significant transformation as organizations seek to streamline their hiring processes and enhance candidate experiences. Leaders in standalone talent acquisition include prominent companies such as Cegid, Dayforce, Infor, Oracle, and Paycor. These players are at...
Continue Reading
